prednisone

Patient was managed acutely with calcitonin and was started on prednisone and hydroxychloroquine. The co-occurrence of both MEN 2A and sarcoidosis is rare, adding an unexpected layer of complexity to the diagnosis. The rarity of sarcoidosis co-occurring with MEN 2A highlights the importance of considering a broad differential diagnosis, even in patients with known genetic syndromes, to ensure accurate management.

Aberrant B cell receptor signaling occurs in several B cell neoplasms including follicular lymphoma (treated with zanubrutinib, a BTK inhibitor), mantle cell lymphoma (acalabrutinib, pirtobrutinib, zanubrutinib), marginal zone lymphoma (zanubrutinib), chronic lymphocytic leukemia and small lymphocytic lymphoma (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib), and Waldenström macroglobulinemia (ibrutinib, zanubrutinib)...Pirtobrutinib fails to form a covalent bond and is a reversible BTK inhibitor. The FDA-approvals of rilzabrutinib and remibrutinib (2025) represent the first nononcologic authorizations for BTK antagonists.

This study provides valuable real-world insight into the clinical landscape of DLBCL in Saudi Arabia. Overall outcomes are consistent with international data, although older age and comorbidities remain associated with poorer prognosis. As advanced therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies become more available, further improvements in survival are expected. These findings underscore the need for a national lymphoma registry and continued investment in research infrastructure to guide evidence-based, personalized care.

The patient responded well to prednisone and rituximab. IgG4-related disease may present with atypical posterior uveitis findings and mimic intraocular lymphoma. This entity should be considered in the differential diagnosis of posterior uveitis masquerade syndromes.

P3, N=1440, Recruiting, Merck Sharp & Dohme LLC

P2, N=170, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Jun 2026 --> May 2027 | Trial primary completion date: Jun 2026 --> May 2027

P1, N=300, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> May 2028 | Trial primary completion date: Jun 2026 --> Aug 2027

P1/2, N=89, Completed, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Completed

P3, N=2921, Completed, University of Giessen | Active, not recruiting --> Completed | N=2200 --> 2921 | Trial completion date: Sep 2026 --> Oct 2025

P3, N=3, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting --> Completed | N=356 --> 3 | Trial completion date: Dec 2027 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

Upon R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) treatment, mesoderm-originating ENI (ENI-mesoderm) was significantly associated with inferior progression-free survival and overall survival, as compared to ectoderm-originating ENI (ENI-ectoderm) and endoderm-originating ENI (ENI-endoderm). Regarding immune checkpoints, ENI-ectoderm, ENI-endoderm, and ENI-mesoderm exhibited significant upregulation of LGALS9, PD-L1, and B7-H3, respectively. Our findings thus contributed to a better understanding of crosstalk between lymphoma progression and embryonic development, providing new insights into targeted approaches against germ layer-dependent invasion in cancer treatment.

P2/3, N=526, Recruiting, Sanofi | Not yet recruiting --> Recruiting